Novartis Ag (NVS) Total Current Liabilities (2009 - 2025)

Novartis Ag's (NVS) quarterly Total Current Liabilities came in at $27.3 billion in Q4 2025, down 4.93% year-on-year from $28.7 billion in Q4 2024, and down 13.99% quarter-over-quarter from $31.7 billion in Q2 2025.

Novartis Ag (NVS) Total Current Liabilities (2009 - 2025) Analysis & Trends

Novartis Ag has disclosed Total Current Liabilities across 12 years of filings, most recently posting $27.3 billion for Q4 2025.

  • Total Current Liabilities for Q4 2025 came in at $27.3 billion, down 4.93% year-over-year; the trailing twelve-month figure through Dec 2025 was $27.3 billion (down 4.93% YoY), and the FY2025 annual result was $27.3 billion, down 4.93% from the prior year.
  • Total Current Liabilities came in at $27.3 billion for Q4 2025 at Novartis Ag, down from $31.7 billion in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $31.9 billion in Q2 2023 to a low of $25.2 billion in Q2 2021.
  • The 5-year median for Total Current Liabilities is $28.2 billion (2022), against an average of $28.5 billion.
  • Across the five-year window, Total Current Liabilities climbed 15.42% in 2023 and dropped 13.47% in 2024, its largest moves.
  • Novartis Ag's Total Current Liabilities stood at $30.2 billion in 2021, then dropped by 5.14% to $28.7 billion in 2022, then slipped by 7.91% to $26.4 billion in 2023, then climbed by 8.72% to $28.7 billion in 2024, then declined by 4.93% to $27.3 billion in 2025.
  • The last three Total Current Liabilities figures came in at $27.3 billion (Q4 2025), $31.7 billion (Q2 2025), and $28.7 billion (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -30.24 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 36.63 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 57.72 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 42.10 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 26.95 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 24.96 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 9.48 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 34.35 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 19.16 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 27.28 Bn
Jun 30, 2025 31.71 Bn
Dec 31, 2024 28.69 Bn
Jun 30, 2024 27.61 Bn
Dec 31, 2023 26.39 Bn
Jun 30, 2023 31.91 Bn
Dec 31, 2022 28.66 Bn
Jun 30, 2022 27.65 Bn
Dec 31, 2021 30.21 Bn
Jun 30, 2021 25.20 Bn
Dec 31, 2020 33.06 Bn
Jun 30, 2020 22.50 Bn
Dec 31, 2019 28.23 Bn
Jun 30, 2019 23.40 Bn
Dec 31, 2018 29.56 Bn
Jun 30, 2018 23.00 Bn
Dec 31, 2017 23.40 Bn
Dec 31, 2016 22.21 Bn
Mar 31, 2010 17,432.00
Dec 31, 2009 19,470.00